KemPharm Analyst Ratings
KemPharm Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/15/2022 | 228.95% | Canaccord Genuity | → $20 | Initiates Coverage On | → Buy |
| 08/17/2022 | 64.47% | HC Wainwright & Co. | $11 → $10 | Maintains | Buy |
| 01/31/2022 | 80.92% | HC Wainwright & Co. | $10 → $11 | Upgrades | Neutral → Buy |
| 04/09/2021 | 64.47% | HC Wainwright & Co. | $12 → $10 | Maintains | Neutral |
| 03/04/2021 | 97.37% | HC Wainwright & Co. | $24 → $12 | Downgrades | Buy → Neutral |
| 01/25/2021 | 360.53% | Roth Capital | → $28 | Initiates Coverage On | → Buy |
| 05/20/2020 | -75.33% | HC Wainwright & Co. | $2.5 → $1.5 | Reiterates | → Buy |
| 11/20/2019 | -58.88% | HC Wainwright & Co. | $3 → $2.5 | Reiterates | → Buy |
| 09/05/2019 | -82.73% | Roth Capital | $4.25 → $1.05 | Downgrades | Buy → Neutral |
| 06/19/2019 | -50.66% | HC Wainwright & Co. | → $3 | Initiates Coverage On | → Buy |
| 05/23/2018 | 179.61% | Janney Montgomery Scott | → $17 | Initiates Coverage On | → Buy |
| 02/26/2018 | 80.92% | Canaccord Genuity | $7 → $11 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2022 年 9 月 15 日 | 228.95% | Canaccord Genu | → 20 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/17/2022 | 64.47% | HC Wainwright & Co. | 11 美元 → 10 美元 | 維護 | 買 |
| 01/31/2022 | 80.92% | HC Wainwright & Co. | 10 美元 → 11 美元 | 升級 | 中性 → 買入 |
| 2021 年 9 月 4 日 | 64.47% | HC Wainwright & Co. | 12 美元 → 10 美元 | 維護 | 中立 |
| 2021 年 4 月 3 日 | 97.37% | HC Wainwright & Co. | 24 美元 → 12 美元 | 降級 | 買入 → 中性 |
| 01/25/2021 | 360.53% | 羅斯資本 | → 28 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/20/2020 | -75.33% | HC Wainwright & Co. | 2.5 美元 → 1.5 美元 | 重申 | → 購買 |
| 2019 年 11 月 20 日 | -58.88% | HC Wainwright & Co. | $3 → 2.5 美元 | 重申 | → 購買 |
| 09/05/2019 | -82.73% | 羅斯資本 | 4.25 美元 → 1.05 美元 | 降級 | 買入 → 中性 |
| 06/19/2019 | -50.66% | HC Wainwright & Co. | → 3 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/23/2018 | 179.61% | 詹尼蒙哥馬利斯科特 | → 17 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2018 年 2 月 26 日 | 80.92% | Canaccord Genu | 7 美元 → 11 美元 | 維護 | 買 |
KemPharm Questions & Answers
KempHarm 問題與解答
The latest price target for KemPharm (NASDAQ: KMPH) was reported by Canaccord Genuity on September 15, 2022. The analyst firm set a price target for $20.00 expecting KMPH to rise to within 12 months (a possible 228.95% upside). 3 analyst firms have reported ratings in the last year.
Canaccord Genuity於2022年9月15日公佈了KempHarm（納斯達克股票代碼：KMPH）的最新目標股價。該分析公司將目標股價定爲20.00美元，預計KMPH將在12個月內升至12個月內（可能上漲228.95％）。去年有3家分析公司公佈了評級。
The latest analyst rating for KemPharm (NASDAQ: KMPH) was provided by Canaccord Genuity, and KemPharm initiated their buy rating.
Canaccord Genuity對KempHarm（納斯達克股票代碼：KMPH）的最新分析師評級由Canaccord Genuity提供，KempHarm啓動了買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KemPharm, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KemPharm was filed on September 15, 2022 so you should expect the next rating to be made available sometime around September 15, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與KempHarm的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。KempHarm的最新評級是在2022年9月15日公佈的，因此您應該預計下一個評級將在2023年9月15日左右公佈。
While ratings are subjective and will change, the latest KemPharm (KMPH) rating was a initiated with a price target of $0.00 to $20.00. The current price KemPharm (KMPH) is trading at is $6.08, which is within the analyst's predicted range.
雖然評級是主觀的，而且會發生變化，但最新的KempHarm（KMPH）評級最初設定爲0.00美元至20.00美元。KempHarm（KMPH）目前的交易價格爲6.08美元，在分析師的預測區間內。